| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Salinomycin is a polyether ionophore antibiotic that is produced by the bacterium Streptomyces albus. It was first isolated in 1979 and has been found to have a range of biological activities, including antibacterial, antifungal, and anticancer properties. It has been shown to induce apoptosis (programmed cell death) in a range of cancer cell lines, including breast, lung, and colon cancer cells. Salinomycin has also been found to inhibit the growth of cancer stem cells. Salinomycin, a widely used antibiotic in poultry farming Actions: -Strong activity against cancer stem cells -Disrupts mitochondrial ion gradients → ROS -Non-thiol, non-NRF2 dominant Key pathways -Mitochondrial K⁺ dysregulation -ROS-mediated apoptosis -Wnt/β-catenin inhibition Chemo relevance -Generally compatible or synergistic -Not a redox buffer
|
| Source: HalifaxProj (inhibit) |
| Type: |
| mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status. mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation. mTor Inhibitors: -rapamycin (Sirolimus): classic natural product mTOR inhibitor -Curcumin -Resveratrol -Epigallocatechin Gallate (EGCG) -Honokiol |
| 4901- | DCA, | Sal, | Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer |
| - | Review, | NSCLC, | NA |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| 4912- | Sal, | Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | H157 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:203 Target#:209 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid